Albert, I don't deny that the 10-12G can provide valuable

New Post Public Reply Private Reply Replies (0) Message Board
Buildit AlbertD #20803
267
Albert, I don't deny that the 10-12G can provide valuable information. That was clearly not at all my point. And maybe it technically doesn't require an EFFECT, although someone on this board interacted with the SEC on this matter, and the SEC indicated an EFFECT would be posted.

If you look at the NGIO Edgar page, the first thing you see chronologically is a 10-12G. That is then followed by 3 letters from the SEC, spanning months, which request needed information from a new company. Those letters were, as far as any reader can tell, completely ignored, and their requests were not fulfilled in any sort of a timely manner. As a result, they were posted as a punitive measure by the SEC, a punishment that was called out in the letters and apparently had no effect.

So at best it does not bode well for a company to have this as their leading information stream as a potential investor tries to analyze whether they want to invest or not. An investor is not going to be impressed that the CEO didn't respond to threats from the SEC, and the SEC felt the need to air this dirty laundry.

Furthermore, this potential investor (who, until we uplist and raise the SP is an individual, most likely not trained as a CFP, broker, etc.) isn't going to know that a Form EFFECT isn't needed. They are going to digest the info in front of them.

So whether an EFFECT is required or not, it is my opinion that a potential investor can either rely on the information available to them on the SEC site, or they can take second-hand remarks on a chat board from a CEO they don't know who gives it the old "everything is ok!".

My (potentially incorrect) interpretation is that there is no way the SEC allowed the automatic approval of the Form 10-12G when they had outstanding requests for information which were, per the SECs posted letters, blatantly ignored for months.

So as the investor continues to read on, they see 3 amendments to the 10-12G, the latest of which was filed on 8-13, less than 60 days ago.

How is an investor supposed to rest assured that the requests for information from the SEC have been completely fulfilled? Should they have assumed that happened when the first amendment was filed on 6-12? If so, why were the next 2 amendments required?

All I'm saying is, until something like the S-1 filing occurs that proves the 10 is truly cleared and accepted, I'm not going to believe a hand-me-down comment from Joe that all is as it should be. He has not shown any ability to-date to navigate this process as he or anyone else has predicted or expected.

I'm not suggesting people sell shares or anything. I still have never sold a share, and I have added as recently as last week. However, I will not be taking Joe's word on any important matters regarding GNBT or NGIO when there is information available to me that can cause a reasonable doubt.

That is, unfortunately, where I am until Joe puts a few of these regulatory requirements and deals successfully in the rear view mirror.


As far as your CYDY comparison goes, I appreciate your idea. I am also a shareholder there. But I believe this is an apples to oranges comparison. ~$3B mkt cap, no toxic financing (partially due to that mkt cap), etc. They are not dealing with as many bottom-feeders as GNBT, so the margin for error is not as slim as what we have here.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading

Top 5 Most Recently Viewed Articles

Major Refinancing Deal in Multifamily Sector by Newmark Group

Updated Category News Views 168

Newmark Group Secures $690 Million for West Shore Portfolio Newmark Group, Inc. (NASDAQ: NMRK), a prominent name in commercial real estate advisory, has successfully arranged a substantial $690 million loan aimed at refinancing a diverse collection of 13 multifamily properties owned by West Shore. These properties are located in several states, including vibrant areas...

Continue Reading
MassageLuXe Expands Its Relaxation Services in Grand Rapids

Updated Category News Views 193

MassageLuXe Expands Its Relaxation Services in Grand Rapids MassageLuXe, a leading spa franchise known for its exceptional massage, facial, and waxing services, is gearing up to enhance wellness offerings in the Grand Rapids area. This strategic initiative marks the company's intent to further establish its footprint in Michigan's second-largest city, driven by the...

Continue Reading
Taylor Heise Joins Upper Deck: A Milestone in Women's Sports

Updated Category News Views 454

Taylor Heise Joins Upper Deck's Elite Team of Athletes Leading the charge in the realm of sports collectibles, Upper Deck recently announced an exciting partnership with Taylor Heise, a standout player in the Professional Women's Hockey League (PWHL). This collaboration highlights the growing prominence of women athletes in sports collectibles, specifically with Heise,...

Continue Reading
Eminent Gold Strengthens Team with Ivan Bebek's Expertise

Updated Category News Views 81

Eminent Gold Welcomes Ivan Bebek as Strategic Advisor Eminent Gold Corp. (TSXV: EMNT) (OTCQB: EMGDF) is making headlines with the recent appointment of Ivan Bebek as a Strategic Advisor for Corporate Development and Finance. This strategic move aims to bolster the company's efforts in identifying and advancing new gold discoveries in Nevada. Ivan Bebek: A Wealth of...

Continue Reading
B. Riley Financial Plans Hearing for Nasdaq Compliance Status

Updated Category News Views 167

Understanding B. Riley Financial's Nasdaq Situation B. Riley Financial, Inc. (Nasdaq: RILY) has announced a significant event regarding its listing status on the Nasdaq exchange. The company received a Staff Determination Letter from the Nasdaq Listing Qualifications Staff, pointing out non-compliance issues that date back to earlier notifications. These notifications...

Continue Reading